Recruiting

Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression

This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=228) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and/or anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines/recommendations guided therapy (control intervention).

I'm interested View official listing

ClinicalTrials.gov IDNCT06853587

PhaseNA

Enrollment228

SponsorUniversity of Calgary

Age12 Years and older

SexALL

I'm interested View official listing

Conditions studied

Anxiety and Depression

About this study

Interventions

Other: Pharmacogenetic-guided dosing — SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
Other: Current prescribing guidelines/recommendations — SSRI dosing based on current prescribing guidelines/recommendations

Primary outcomes

Number of participants with depression remission (Baseline to 12 weeks)
Number of participants with anxiety remission (Baseline to 12 weeks)

Eligibility information

Inclusion Criteria: * Age 12-17 * Depression and/or anxiety as the primary concern, confirmed by the treating physician * Intention to start a new SSRI * English fluency Exclusion Criteria: * Co-occurring obsessive compulsive disorder, psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability * History of non-response to 3 or more SSRI medications as confirmed by the treating physician * Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate/change brain stimulation during study participation * History of liver or hematopoietic cell transplant * History of CYP2B6, CYP2C19, or CYP2D6 testing

Study locations

University of Calgary, Calgary, Alberta T2N 4N1 Canada

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.